The global biomarker clinical phase outsourcing services market is anticipated to grow at a considerable CAGR of 21.3% during the forecast period (2023-2030). The increasing utilization of biomarkers for several chronic diseases has significantly propelled the market growth. The diverse range of biomarkers and their applications in monitoring and diagnosing several disorders. Advancements in biomarker technology are increasing the potentials for more personalized treatment, accurate and early disease detection, and improved patient outcomes. Some of the primary biomarkers that are significantly used in several clinical indications, such as-
Browse the full report description of “Biomarker Clinical Phase Outsourcing Services Market Size, Share & Trends Analysis Report by Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, and Surrogate Endpoints), by Therapeutic Area (Oncology, Cardiology, Neurology, and Autoimmune Diseases), and by End-Use (Pharmaceutical Companies and Biotechnology Companies), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/biomarker-clinical-phase-outsourcing-services-market
• CA-125: CA-125 is a biomarker used in the diagnosis and monitoring of ovarian cancer, which screening of high-risk women with ovaries despite its limited sensitivity and specificity. Recent findings suggest that CA125 might also serve as a predictive marker for pre-invasive OC.
• Prostate-Specific Antigen (PSA): PSA is a biomarker used in the screening & monitoring of prostate cancer. The PSA test measures the level of PSA in the blood. In 1994, FDA approved the PSA test to be used in conjunction with a digital rectal exam (DRE) to aid in the detection of prostate cancer in men 50 years and older.
• HER2/neu: HER2/neu is a biomarker used to recognize breast cancer patients who may benefit from targeted therapies. HER2/neu on cancer cells is measured in 2 ways. Immunohistochemistry (IHC) testing checks for this protein on the surface of cancer cells. Fluorescence in situ hybridization (FISH) tests for the genes that direct the cell to make HER2/neu protein.
• S100B: S100B is a biomarker utilized in traumatic brain injury (TBI) monitoring and diagnosis. S100b is specifically found in the cytoplasm and nucleus, and less than 1% of this protein is secreted in a regulated fashion. Elevated CSF S100b levels after severe brain injury may reflect ongoing structural damage and cell death.
• BNP (B-type natriuretic peptide): BNP is a biomarker used for diagnosing heart failure and assessing its severity. B-type natriuretic peptide (BNP) is a member of a family of natriuretic peptides (NP) that include atrial natriuretic peptide (ANP), C-type natriuretic peptide, D-type natriuretic peptide, and urodilatin.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Type
o By Therapeutic Area
o By End-Use
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Celerion, Fujirebio Europe NV, ICON plc, and Parexel International Corp., among others.
Key questions addressed by the report
Global Biomarker Clinical Phase Outsourcing Services Market Report Segment
By Type
By Therapeutic Area
By End-Use
Global Biomarker Clinical Phase Outsourcing Services Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/biomarker-clinical-phase-outsourcing-services-market